Objective This survey investigated the level of public awareness, preference, and motivation of novel psychoactive substances (NPS) use as well as knowledge of potential associated health risks.
| INTRODUCTION
Novel psychoactive substances (NPS) represent a bewildering array of unregulated psychoactive compounds with slight differences in their chemical structures to mimic effects of traditional illicit drugs and are marketed globally as legal alternatives (so-called 'legal high') to wellknown controlled drugs (EMCDDA-Europol, 2016a) . There is debate around nomenclature and definition (King & Nutt, 2014) , but within Europe most researchers use the term NPS (EMCDDA, 2011 (EMCDDA, , 2014 .
The last decade has witnessed the rapid emergence of NPS sold over the internet and in 'head-shops'. The content, interactions, side-effects, and abuse potential of these NPS are often unknown, not only to users but also to health care professionals. There are many gaps in knowledge related to NPS acute and long-term effects. Typical sideeffects that have been noticed in users of NPS are psychosis, hallucinations, tachycardia, seizures, and organ toxicities (Stephenson & Richardson, 2014) . There are increasing numbers of deaths associated with NPS (Corkery et al., 2015) , although in most cases the deceased are polysubstance users and the contribution that individual drugs made to death cannot always be accurately determined in such cases.
The emergence of NPS has created a challenge for drug policymakers worldwide and a substantial global threat for public health.
Most NPS are not controlled under the international drug control conventions, and their legal status differs from country to country (UNODC, 2014) . The United Nations Office on Drugs and Crime (UNODC) indicates that 102 countries and territories from all regions of the world have reported the emergence of NPS in their drug markets (UNODC, 2016) . Up until December 2015, 644 novel substances were reported to the UNODC Early Warning Advisory (UNODC, 2016) . In 2014, one in five Americans told the Global Drugs Survey (GDS) that they had taken an NPS in the last year-more than any other country in the world (GDS, 2014) . In Europe, there has been a very rapid increase in use of NPS, according to early warning system data provided to the EMCDDA over the period [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] . The EU early warning system is currently monitoring over 590 novel substances; in 2015, 98 new substances were reported for the first time (EMCDDA, 2015b (EMCDDA, , 2016b ).
The UK is one of the biggest consumers of NPS in Europe (GDS, 2016) with frequent reports of serious clinical and public health issues, particularly for vulnerable groups (prisoners, teenagers, and homeless).
The GDS reports that 58% of NPS were purchased online in the UK last year, and NPS users are three times more likely to end up seeking emergency medical treatment than using traditional drugs (GDS, 2016) . The risk of potential harms, that is, long-term mental health issues, crime, debt, and violence has prompted the UK government to bring in the Psychoactive Substances Act 2016 banning the production, supply, importation, and exportation of NPS (The Stationary Office/TSO, 2016).
There are a number of websites (international, national, and local) dedicated to providing information on NPS (e.g., http://www. talktofrank.com and https://www.globaldrugsurvey.com/brand/thehighway-code). In contrast, users (e.g., drug-related internet fora) and internet sales sites often provide unregulated, user-led source information, which may not present an accurate picture and can be intentionally misleading to (potential) consumers (Davey, Schifano, Corazza, Deluca et al., 2012) . The largely outdated and misleading term 'legal high' implies that there had been some process of assessment deeming these substances safe for human consumption. Awareness that "if something is legal it does not mean it is safe" and anything you consume is potentially unsafe does not necessarily register with (potential) consumers. For consumers, it is simply a matter of how much of it you need to consume that is important.
A number of surveys have investigated the pattern of NPS use, although few surveys capture the user's perceptions of NPS safety (McElrath & O'Neill, 2011) and the educational background of respondents. Understanding consumer perceptions of NPS safety could enhance targeted prevention interventions. This international online survey was designed with two aims -first, to provide data on the international patterns of NPS awareness, use, preference, motivations, experiences, and health perceptions (the basis for this paper) and second, to provide data specifically on ketamine use (not presented here). The educational background and employment status of respondents were also collected. Some of these survey findings have been presented at the IVth Novel Psychoactive Substances conference (Deligianni, Corkery, & Lione, 2016) .
| METHODS
In order to elicit the views of individuals, especially young people, and to get as wide a range of views in a short time, an online survey was considered to be the most appropriate method. This approach has been previously used by the second and third authors in recent years in order to obtain information on NPS.
The survey was developed using Bristol Online Survey (www.
survey.bris.ac.uk), a Web survey development service with wide readership. This product was used as it is freely available to the University of Hertfordshire, provides analytical tools, and is easy to use. The survey instrument was designed to capture patterns of NPS and ketamine awareness (had they heard of NPS or legal high or ketamine), use, preference, motivations, experiences, and health perceptions. There were 32 structured questions split into four sections.
The first two sections were mandatory (10 questions on demographics and NPS awareness, use, and perceived harms). Respondents were informed that they should only complete the third section if they had taken an NPS on at least one occasion in the past. Finally, the fourth section was specific to those that had taken ketamine on at least one occasion in the past. A copy of the survey will be provided upon request.
Following a pilot involving six university students, no changes to the survey were necessary. The survey was in English and advertised on the drug forum Bluelight (www.bluelight.org) and promoted using social media facebook pages (via personal contact pages, 
| RESULTS
The survey was completed by 168 respondents from 17 countries during the month it was available online.
| Demographics
Respondents were mainly from Europe (149; 89%). The UK (97; 58%, with over half in England) and Greece (34; 20%) represented the main component of European respondents. Outside of Europe, respondents were mainly from the United States (10; 6%) whilst other countries represented less than 3% of respondents. Respondents were mostly female (63%), aged 18 to 25 years (83%), heterosexual (92%; 
| NPS awareness
Two-thirds (109, 65%) of respondents considered themselves aware of NPS; the most aware in this group were from the UK (71; 72%), Australia (3; 75%), and the Far East and Asia (3; 67%). In Europe (excluding the UK) and US/Canada, NPS awareness dropped to (27) 52% and (6) 55%, respectively. Given the low numbers of respondents from some countries, caution must be used when comparing data between the different countries. There was equal awareness of NPS amongst males and females (both 65%), with reduced awareness in only the 26-35 years age group (8; 50%). Sexual preference impacted NPS awareness as bisexual and homosexual respondents (13 out of 14; 93%) were significantly more NPS aware than heterosexuals (96 out of 154; 62%, p < .019, Chi-square test, Table 3 ). Age group and higher educational status did not alter NPS awareness, although undergraduates were more aware (81 out of 112; 72%) than postgraduates (14 out of 28; 50%). Employed respondents were significantly more aware (62; 75%) than the unemployed (39; 55%) (chi-square test, p < .013, Table 3 ).
| NPS use
Of the total 168 respondents, 24 were NPS users (14%); which accounted for 22% of the 109 NPS-aware respondents (Table 4 ).
There were fewer NPS users from Europe (excluding UK; 4 out of 52; 7%) and Australia (0 out of 4; 0%) and more users from the Far East and Asia (1 out of 3; 33%); caution must be taken when comparing these groups because of size. There were twice as many male respondents (13 out of 63; 20%) using NPS than females (11 out of 105; 10%) although the male and female respondents were equally NPS aware (Table 4 ). The age group with the highest proportion of NPS users (excluding <18 and >50 years-only two respondents) was the 18-25 one (70%), followed by 36-50 (17%) and 26-35 (13% ; Table 4 and chi-square test, p < .004, Table 5 ).
Even though most of the NPS users (20 out of 24, 83%) had studied at university and were employed, the percentage of NPS use versus non-use was unaffected by educational level. Those educated to college or school level and those educated to university level both had NPS use of 14%. In contrast, employment status significantly increased NPS use (6% NPS users were unemployed, 4 out of 71;
and 24% NPS users were employed, 20 out of 83, 3.4 | Motivations, effect profile or experiences, preference, and health perception of NPS use Two-fifths (40%) of nonusers felt that NPS were safer than illegal drugs whilst half (50%) felt that NPS should be made illegal. In contrast, only 12% of users felt that NPS were safer than illegal drugs (Table 4) .
Half (50%, 72 out of 144) of nonusers gave the main reason for not On the current employment status were reported responses such as fulltime research student, full-time master student, and student in gap year.
using NPS as awareness of serious health complications associated with their use (Table 6 ).
The main motivation in using NPS for two-thirds (16/24) of the NPS users was having friends taking them. The fact that NPS were legal and gave "a high" was also a motivation for half the users (Table 7) . The main positive effect noted by users after taking NPS was feeling relaxed (67%), whilst 33% reported experiencing anxiety or hallucinations and 30% had lower inhibitions and a faster heart rate (Table 8) . Two-fifths (38%, 9 out of 24) of users noted other effects, including difficulty sleeping, often if more than one drug was taken.
Alcohol was most commonly reported to be taken in combination with NPS (33%).
The majority of NPS users had used both an NPS and ketamine at least once (there were 24 responses to their preferred NPS and 19 responses to ketamine from the 24 users). Seventy-one percent (17) of users had taken the "other" category of NPS with a preference for nitrous oxide, benzo-fury, mephedrone, or "spice." Four-fifths (79%) of users had used ketamine at least once and in preference to its legal derivatives (in many countries), methoxphenidine (MXP; 8%; 2), MXP (12%; 3), and diphenidine (8%; 2). Most (85%, 20) of the users reported only occasional use of NPS (less than once a month), 12% (3) reported often use (approximately once every 2 weeks) whilst 4% (1) reported use of NPS very often (more than 3 times per week). Half (51%, 12) of the users perceived NPS to carry a medium to high risk to health, whilst 20% (5) thought they carried a low risk and 29% (7) did not know whether or not NPS posed a health risk.
| DISCUSSION
Even though more than 80% of respondents were university educated 18-to 25-year-olds, one-third (35%) were unaware of NPS. Males and females were equally unaware of NPS. Fourteen percent of our respondents were users of NPS (22% of the NPS-aware group) with a higher trend of NPS use in males (20%) than females (10%, p = .07). The higher use by males should also be considered in the context of the self-selecting nature of the survey sample, which was mainly female (62.5%). The rate of female (and Note. NPS = novel psychoactive substances.
*Correlation is significant at the .01 level (two tailed; chi-squared test, two-tailed). Note. NPS = novel psychoactive substances. There were reported difficulties in sleeping, feeling that "sleep would never come again" (use of more than one substances mixed together), happiness and not any changes.
Greek and University) respondents is unusually high (NPS surveys are usually weighted towards male respondents) as our survey was advertised mainly via university groups and personal accounts via the first author of this paper (a female Greek national) to enable a rapid response rate during the short survey period. In line with our findings, the CSEW notes that males (1.1%) were more likely to have used NPS in the last year than females (0.4%) and they show that ketamine misuse is most common in young males, which may be reflected in our survey, as 79% of our NPS users also used ketamine. The Home
Office (2016) and Asia have higher rates of NPS use in our survey, this will, in part, be explained by sampling differences (89% respondents were from Europe). Also given that the control status of NPS differs between countries, the "other" substances that respondents used and considered as NPS may have differed between countries.
NPS use was significantly affected by the age of the respondents (p < .01) and those in employment (p < .01). Age clearly matters although the age effect will have been skewed by sampling differences as the response level is very low in the older groups (e.g., 27
respondents were over 26 years compared to the 141 respondents aged less than 25 years). Other surveys indicate that ageing is seen as a protective factor for NPS use (Home Office, 2014b). The majority of NPS users in our survey also used ketamine, and UK population surveys show an increase in ketamine use in all adults (16-59) and young people (16-24), which may account for the increase in mean age of our NPS users.
Unlike typical heroin and crack cocaine users, club drug users (i.e., NPS or ketamine users) often have good personal resources -jobs, relationships, and accommodation (National Treatment Agency, 2012). In line with this, we noted that the employment status of our respondents significantly altered NPS awareness and use. Employed respondents, particularly those in full-time jobs, were more NPS aware (84%) compared to unemployed respondents (55%, p = .013). NPS awareness also influenced use as NPS users were more likely to be employed (24%) rather than unemployed (6%). According to emerging clinical opinion and data, club drug users have jobs, are socially functional, and are often highly educated (National Treatment Agency, 2012). Interestingly, undergraduates were more NPS aware (72%) and more likely to use NPS (16%) than postgraduate respondents (50% aware, 8% use) indicating that a higher level of educational status is not a factor related to NPS awareness or use. Here, we show that, irrespective of whether a respondent is college, school, or university educated, such experience fails to influence NPS awareness or use (p > .05) clearly indicating a need for improved drugs education.
NPS commonly used were the synthetic cannabinoid receptor agonist "Spice," the synthetic cathinone mephedrone, the benzofuran benzofury, benzodiazepine analogues, and nitrous oxide. Common use of these NPS is widely reported in other surveys (GDS, 2016; Penney, Dargan, Padmore, Wood, & Norman, 2016) . Extensive research shows that 83% to 99% of NPS users are also users of other traditional illicit drugs (Home Office, 2014a) and preference for traditional illicit controlled drugs over their related NPS is commonly seen (Penney et al., 2016; Winstock & Barratt, 2013) . Seventy-nine percent of our NPS users had also used controlled ketamine; however, our survey did not ask users about their other illicit drug use so this percentage may well be higher. We also noted that 79% of our users used ketamine compared to only 8-12% that used the ketamine legal derivatives methoxetamine (MXE), MXP, and diphenidine. User preference for ketamine over MXE is similar to a recent survey of 7,700 UK-based polydrug users where only 5% of the sample had ever used MXE and 4.2% reported last 12 month use of MXE compared with 49% for ketamine (Winstock, Lawn, Deluca, & Borschmann, 2016) . London school children also have a preference for ketamine (48%) over MXE (29%, Penney et al., 2016) . Further, some users have stated that the effects (such as depression and extremely intense experiences) of taking MXE with ketamine are more unpleasant than ketamine alone these may deter MXE use. Recreational ketamine and/or NPS, especially when taken with other substances like alcohol (one third of users reported alcohol use) can affect breathing and increase heart rate, and cause feelings of anxiety and depression (Home Office, 2014a). These effects were reported by our users, despite the fact that most were infrequent users (less than once a month).
Our findings are in line with GDSs (2015) that NPS generally do not have an effect profile that is preferred to traditional drugs by the vast majority of users and very importantly are not seen as safer than traditional drugs, despite claims on internet websites that these are safer alternatives (e.g., MXE is safer and less damaging to the bladder compared with ketamine, Morris, 2011) . Half of our users (12) were aware that NPS carried potential medium to high health risks and only 12% (3) felt NPS were safer than illegal drugs. Despite over half of our users being risk aware that NPS carry a medium to high risk to health, they still chose to get high. In contrast, regardless of the fact that only and legal status to potential users. Often, the knowledge people have about NPS is gained through peer to peer interactions, or online fora, which can reinforce a variety of myths and misconceptions (Davey et al., 2012) . Being able to easily buy NPS online was a major motivator for 42% of our users, and the latest GDS (2016) report show 58% users in the UK purchased online. The fact that 83% of our users either had a degree or were studying for a degree confirms that 'e-Psychonauts'
are typically well educated and well informed (Schifano et al., 2006) .
Our survey highlights that for many nonusers and users alike, there is a lack of education on NPS awareness and health risks of NPS use. For many of our respondents, information is sourced via the media and internet, which can often result in misinformation and misperceptions (Davey et al., 2012) . Public opinion across Europe ranks information and prevention campaigns as the second most important way for policy makers to tackle society's drug problems (second to punishing drug dealers and traffickers, European Commission, 2014a), and the GDS High-way Code guide "to a safer more enjoyable drug use" was voted for by almost 80,000 people from across the world for reducing the risks of harm whilst impacting little on pleasure (GDS, 2014) . Implementation of the UK Psychoactive Substances Act 2016 will need to work in tandem with a comprehensive education and targeted public awareness campaign (ideally via media and internet) highlighting the potential risks and harms from these substances, particularly for the more vulnerable risk-taking 16-to 24-year-olds, parents, and teachers (Lione, 2016) . Currently, science is the only statutory subject that delivers drug education in UK schools, and this is largely confined to biological understandings of drugs (DfE, 2013) . Schools are expected to cover other fundamental components of drug education -resilience to risk factors (e.g., peer pressure), social, and emotional skills -within personal, social, and health education (PSHE, DfE, 2012). A recent survey of 590 secondary school pupils in London and 288 teachers across England highlighted the need for an improvement in national policy on drugs education particularly in relation to subject-specific teacher training and the need for a statutory status for PSHE (Thurman & Boughelaf, 2015) . Government support and professional training and development are essential ingredients in the provision of universal drug education in schools (Hargreaves, 2016) . Introducing a statutory PSHE programme into the national curriculum and higher education will not only educate but build resilience and empower young people to help them make positive choices for their health including substance choices when in peer pressure situations. Applying this evidence-based approach to drugs education is also recommended by the EMCDDA (2015a; 2016a).
| Strengths and weaknesses of the study
There are a number of strengths in this study.
The survey was open to the general public, and the majority of respondents were UK University students aged 18 to 25 years, the most dynamic NPS user group. When used alongside other sources, this survey helps build a more in-depth picture on the awareness and use of NPS, particularly in educated and employed individuals, and identifies a need for improved drugs education.
This study has some limitations. The recruitment window was brief with the survey active for only 4 weeks and only available online and will therefore tend to miss those without easy online access and those with who do not speak English. The major methodological limitation with this survey is the sampling bias and the variation in size of the samples from different countries (mainly from the UK and Greece).
This means caution must be used when comparing data between the different countries. The self-selecting sample were typically in their 20s and 30s and well educated and one suspects may have a greater interest in the topic. Of note is that the high 18 to 24 age-group sample are also more likely to go clubbing hence may be more drug aware and experienced than the general population. Advertisement of the survey through wider professional associations and organisations and drug and science fora could have led to a greater range of public response.
| CONCLUSIONS
We have shown that awareness of NPS and, importantly, perceptions of the potential health risks associated with NPS use was lacking in a sample of predominantly university educated people. NPS use was higher in those in employment, was unaffected by their level of education, and was influenced by factors including age, friends or peers, and legal status. The fact that NPS awareness and use was higher in undergraduates compared with postgraduates requires further investigation.
Although this small international pilot survey had availability bias to well-educated young people, mainly from the UK and Greece, similar trends to larger GDSs were noted. It is important that reliable and up-to-date survey data are available to inform education and policy in this area. The fact the majority of the sample were university educated highlights a need for targeted drugs education intervention by policy-makers in schools and universities. Publishing results from such surveys will also inform the public so they are risk-aware and can make informed and educated choices about whether or not to use NPS, legal or not. 
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